Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) Compared With Egg-Based Quadrivalent Influenza Vaccine (IIV4) in Participants Aged 3 to 8 Years

Clinical trial NCT05513391 · TERMINATED

Trial details

NCT number: NCT05513391
Sponsor: Sanofi Pasteur, a Sanofi Company
Status: TERMINATED
Phase: Phase 3
Study type: INTERVENTIONAL

Influenza Immunization

Start date: 2022-11-10
Primary completion: 2023-10-03
Enrollment: 366

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.